DE10257478A1 - Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis - Google Patents
Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis Download PDFInfo
- Publication number
- DE10257478A1 DE10257478A1 DE10257478A DE10257478A DE10257478A1 DE 10257478 A1 DE10257478 A1 DE 10257478A1 DE 10257478 A DE10257478 A DE 10257478A DE 10257478 A DE10257478 A DE 10257478A DE 10257478 A1 DE10257478 A1 DE 10257478A1
- Authority
- DE
- Germany
- Prior art keywords
- composition according
- osteoporosis
- vitamin
- treatment
- periodontitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 6
- 208000001132 Osteoporosis Diseases 0.000 title claims description 11
- 230000002265 prevention Effects 0.000 title claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 6
- 208000035475 disorder Diseases 0.000 title 1
- 239000011785 micronutrient Substances 0.000 title 1
- 235000013369 micronutrients Nutrition 0.000 title 1
- 201000001245 periodontitis Diseases 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 230000001154 acute effect Effects 0.000 claims abstract description 6
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 5
- 208000037921 secondary disease Diseases 0.000 claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 8
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 229930003316 Vitamin D Natural products 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 235000019166 vitamin D Nutrition 0.000 claims description 6
- 239000011710 vitamin D Substances 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003448 Vitamin K Natural products 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 235000019168 vitamin K Nutrition 0.000 claims description 5
- 239000011712 vitamin K Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 208000030653 Jaw disease Diseases 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 208000024693 gingival disease Diseases 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940035936 ubiquinone Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 description 4
- 229940046010 vitamin k Drugs 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000000515 tooth Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001909 alveolar process Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002436 femur neck Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- -1 B. in aloe vera Chemical class 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Die Anmeldung betrifft eine Zusammensetzung, umfassend einen Gehalt an Antioxidantien und Vitalstoffen sowie geeignete Hilfs- und Trägerstoffe zur prophylaktischen und/oder akuten Behandlung von Parodontitis sowie damit einhergehenden Begleit- und/oder Folgeerkrankungen.The application relates to a composition comprising a content of antioxidants and vital substances as well as suitable auxiliaries and carriers for the prophylactic and / or acute treatment of periodontitis as well as accompanying and / or secondary diseases associated therewith.
Description
Die vorliegende Erfindung betrifft eine Zusammensetzung zur prophylaktischen und/oder akuten Behandlung von Parodontitis sowie damit einhergehenden Begleit- und/oder Folgeerkrankungen.The present invention relates to a composition for prophylactic and / or acute treatment of periodontitis as well as accompanying and / or secondary diseases.
In Deutschland lag 1999 die Häufigkeit behandlungsbedürftiger Parodontitiden bei über 75 % und zählen weltweit – nach Karies – zu den am meisten verbreiteten Erkrankungen.The frequency was in Germany in 1999 requiring treatment Periodontitis in over 75% and count worldwide - after Caries - too the most common diseases.
Chronische Zahnfleischentzündungen können die Ursache verschiedener Erkrankungen sein. Bei chronischen Erkrankungen von Zahnfleisch und Zahnbett dringen Entzündungen auslösende Bakterien auch in die Blutgefäße ein. Dort aktivieren sie immunkompetente Zellen der körpereigenen Abwehrkräfte. Auf diesen Reiz hin produzieren die alarmierten Immunzellen dann Zytokine, d.h. zerstörerische Botenstoffe, die im gesamten Organismus andere Gewebe und Organe schädigen können.Chronic gum infections can be the cause of various diseases. With chronic diseases Inflammatory bacteria penetrate the gums and the tooth bed also in the blood vessels. There they activate immune-competent cells of the body's defenses. On the alarmed immune cells then produce this stimulus, cytokines, i.e. destructive Messenger substances that spread to other tissues and organs throughout the organism damage can.
Beispielsweise können in der Bauchspeicheldrüse die für die Insulinproduktion verantwortlichen Zellen durch permanent erhöhte Zytokinspiegel geschädigt oder sogar zerstört werden. Wenn das der Fall ist, kann Diabetes entstehen. Bakterien, wie Streptococcus sanguis oder Porphyromonas gingivalis können schwere Herzerkrankungen auslösen. Bei Patienten mit fortgeschrittener Parodontitis wurde ein dreifaches Schlaganfallrisiko sowie bei Frauen ein siebenfaches Risiko für Frühgeburten beobachtet.For example, the pancreas can be used for insulin production responsible cells damaged or permanently cytokine levels even destroyed become. If this is the case, diabetes can develop. Bacteria, such as Streptococcus sanguis or Porphyromonas gingivalis can cause serious heart disease trigger. In patients with advanced periodontitis, there was a triple Stroke risk as well as a sevenfold risk of premature birth in women observed.
Aus dem Plaque strömende Enzyme, (z. B. Hyaluronidasen, Kollagenasen und Chondrioitinsulfatasen) Antigene, Endotoxine und Zytokine greifen in das Gewebe ein. Das Gewebe antwortet mit Immunvorgängen, die zu einer Parodontitis und zur Bildung von pathologischen Zahnfleischtaschen, zur Auflösung des Bindege webes mit Knochenabbau, zur Zahnlockerung und letztendlich zum Zahnverlust führen. Das Heimtückische an dieser Erkrankung ist, dass Parodontitis selbst im weit fortgeschrittenen Stadium meist schmerzfrei ist. Die Erkrankung verläuft aufgrund der Verschlechterung der Stoffwechsellage progredient und ist ansteckend.Enzymes flowing out of the plaque, (e.g. hyaluronidases, collagenases and chondrioitinsulfatases) Antigens, endotoxins and cytokines interfere with the tissue. The Tissue responds with immune processes, leading to periodontitis and the formation of pathological gum pockets, for dissolution of the connective tissue with bone loss, for loosening teeth and ultimately lead to tooth loss. The insidious of this disease is that periodontitis is well advanced Stage is usually painless. The disease is due to the deterioration of the metabolism progressively and is contagious.
Es gilt daher ein Mittel zur Verfügung zu stellen, mit welchem man routinemäßig die Entstehung von Parodontitis prophylaktisch entgegenwirken und bereits aufgetretene Parodontitis zurückdrängen kann, um Folgeerkrankungen zu vermeiden.There is therefore a means at your disposal with which one routinely the development of periodontitis counteract prophylactically and periodontitis that has already occurred can push back to avoid complications.
Gegenstand der vorliegenden Erfindung ist demnach eine Zusammensetzung, umfassend einen Gehalt an Antioxidantien und Vitalstoffen sowie geeignete Hilfs- und Trägerstoffe zur prophylaktischen und/oder akuten Behandlung von Parodontitis sowie damit einhergehend Begleit- und/oder Folgeerkrankungen.Object of the present invention is accordingly a composition comprising an antioxidant content and vital substances as well as suitable auxiliary and carrier substances for prophylactic and / or acute treatment of periodontitis and related Concomitant and / or secondary diseases.
Durch die kombinatorische Anwendung von Antioxidantien und Vitalstoffen wird die Stoffwechsellage im oralen Bereich bei – gleichzeitiger Unterdrückung von Entzündungen – optimiert. Die Wirkung ist im Vergleich zur Einzelverabreichung der Komponenten überraschender Weise synergistisch.Through the combinatorial application of antioxidants and vital substances the metabolic situation in the oral area at - simultaneous suppression of inflammation - optimized. The effect is more surprising compared to the individual administration of the components Wise synergistic.
Vorzugsweise weist die Zusammensetzung einen Gehalt an Ubichinon (Q10) und Vitalstoffen, nämlich Vitaminen und/oder Mineralien auf. Die Vitamine umfassen alle gängigen Vitamine der Gruppen A, B, C, D, E und K. Unter den Mineralien sind bevorzugt solche auf Basis von Calcium, Magnesium, Zink, Kupfer, Mangan, Fluor und Phosphor zu erwähnen.Preferably, the composition contains ubiquinone (Q10) and vital substances, namely vitamins and / or minerals. The vitamins include all common vitamins of groups A, B, C, D, E and K. Among the minerals are preferred those based on calcium, magnesium, zinc, copper, manganese, fluorine and mention phosphorus.
Die antibakterielle Wirkung von polyphenolhaltigen Substanzen (z. B. Extrakte von Grünem Tee) führt durch Wachstumshemmung des Bakteriums "Streptokokkus mutans" zur Verbesserung der Zahnfleischqualität und zu einem signifikanten Absinken des Plaqueindexes.The antibacterial effect of polyphenols Substances (e.g. green tea extracts) cause growth inhibition of the bacterium "streptococcus mutans "for improvement the gum quality and a significant decrease in the plaque index.
Weitere vorteilhafte Bestandteile der Zusammensetzungen bilden die Aminosäuren, z. B. in Aloe vera, insbesondere Lysin, die ein wesentlicher Bestandteil des Kollagens, der Sehnen, Knochen und Zähne ist. Lysin blockt die eiweißverdauenden Enzyme (Proteasen) und vermindert somit den Abbau von Zahnfleisch.Other beneficial ingredients the compositions form the amino acids, e.g. B. in aloe vera, in particular Lysine, which is an essential part of collagen, the tendons, Bones and teeth is. Lysine blocks the protein-digesting Enzymes (proteases) and thus reduces the breakdown of gums.
Die erfindungsgemäßen Zusammensetzungen finden demnach bevorzugt Verwendung in der Therapie bei akuten und chronischen Zahnfleisch- und Kiefererkrankungen, bei Osteoporose insbesondere der Osteoporoseprävention. Die Zusammensetzung kann im human- und veterinärmedizinen Bereich in Form von Pasten, Ölen oder in Form von Lutschtabletten Verwendung finden.Find the compositions of the invention therefore preferred use in therapy for acute and chronic Gum and jaw diseases, especially with osteoporosis prevention of osteoporosis. The composition can be in the form of human and veterinary medicine of pastes, oils or in the form of lozenges.
Bevorzugte Zusammensetzungen, in
Form einer Paste, eines Öls
und einer Lutschtablette, sind im Folgenden beispielhaft angegeben. Paste
Gegebenenfalls kann diese Pastenzusammensetzung
Poliermittel und/oder Geschmacksstoffe sowie Trägerstoffe bzw. Bindemittel
beinhalten.
Poliermittel: beispielsweise Dicalciumphosphat-dihydrat
Geschmacksstoffe:
Öle aus Salbei,
Zitrone, Pfefferminz, Menthol und/oder Nelke.
Trägerstoffe/Bindemittel:
Agar-Agar
oder Kieselsäuren,
wie Aerosil® Öl
Polishing agent: for example dicalcium phosphate dihydrate
Flavorings:
Sage, lemon, peppermint, menthol and / or clove oils.
Excipients / Binder:
Agar or silica, such as Aerosil ® oil
Die positiven Wirkungen der oben angegebenen Zusammensetzungen beruhen auf einer Entkeimung von Mund- und Rachenraum, einer Vorbeugung gegen Entzündungen der Atemwege, einer Unterstützung bzw. Entlastung des Immunsystems, einer Vermeidung und Minderung eines starken Mundgeruches, einer Unterstützung bzw. Therapie bei Zahnfleischentzündungen und, nicht zuletzt, einer prophylaktischen und unterstützenden Therapie bei Osteoporose, insbesondere der Kieferknochen.The positive effects of the above specified compositions are based on a disinfection of oral and throat, a prevention of inflammation of the respiratory tract, one Support or Relief of the immune system, avoidance and reduction of one strong bad breath, support or therapy for gingivitis and, last but not least, a prophylactic and supportive one Therapy for osteoporosis, especially the jawbone.
Q10 ist Teil der Elektronentransportkette, um die bei der Glukosespaltung entstehenden hochenergetischen Elektronen zu neutralisieren und ATP zu gewinnen. Ein Mangel führt zur Senkung der ATP-Produktion und damit der Senkung der Zellerneuerung.Q10 is part of the electron transport chain, around the high-energy electrons generated during glucose cleavage neutralize and gain ATP. A lack leads to Lower ATP production and thus lower cell renewal.
Vitamin C fördert die Neuproduktion von Kollagen und Elastinmolekülen. Dadurch wird eine ausreichende Festigkeit des Bindegewebes erreicht.Vitamin C promotes the new production of Collagen and elastin molecules. This ensures sufficient connective tissue strength.
Unter Osteoporose versteht man den beschleunigten und verfrühten Knochenabbau, besonders der Wirbelsäule, des Oberschenkelhalses und am Alveolarfortsatz des Kieferknochens. Die Erkrankung ist durch eine Verringerung der Knochenmasse und eine Verschlechterung der Mikroarchitektur des Knochens gekennzeichnet. 1999 litten ca. 6 Millionen Menschen an Osteoporose.Osteoporosis is the accelerated and premature Bone breakdown, especially of the spine, the neck of the femur and on the alveolar process of the jawbone. The disease is caused by a Decrease in bone mass and deterioration in micro-architecture of the bone. In 1999, about 6 million people suffered of osteoporosis.
Sollen die erfindungsgemäßen Zusammensetzungen auch zur Osteoporoseprävention dienen, ist es vorteilhaft weitere Vitamine und/oder Vitalstoffe zuzusetzen.Are the compositions of the invention also for the prevention of osteoporosis serve, it is advantageous further vitamins and / or vital substances add.
Im folgenden werden die Wirkungsweisen
einiger solcher Komponenten in Kurzform erläutert:
Vitamin D: fördert die
Calciumresorption im Darm; ist am Knochenstoffwechsel beteiligt;
Defizite bei verminderter Sonnenlichtexposition;
Vitamin D-Versorgung
1. über
Nahrung; meistens zu gering
2. Eigenproduktion in der Haut
bei UV Licht.
Vitamin B6: Knochen enthält organische Matrix, deren
Bestandteile Knochenfibrillen sind. Sie sind für die Elastizität der Knochen
verantwortlich.
B6 ist zur Synthese von Knochenkollagen wichtig.
Es besteht eine positive Beeinflussung des knochenaufbauenden weiblichen
Geschlechtshormons Progesteron.
Mangel: durch Umwelttoxine
wie Hydrazine; Verschiedene Herbizide wirken als B6 – Antagonisten.
Vitamin
C: Beteiligung an der Synthese des Knochenkollagens; die Kollagenbiosynthese
verstärkt
die Knochenstabilität;
Aktivierung
von Vitamin D
Bei Vitamin C-Mangel: verringerte Knochenbildung;
verstärkte
Knochenresorption; blutende Gingiva, erklärt durch mangelhafte Kollagensynthese;
Die
Vitamin C-Konzentration ist in speziellen weißen Blutzellen, den sog. polymorphkernigen
neutrophilen Granulozyten (PMN) 10-80 mal höher als im Blutplasma.
Die
Funktion ist:
Aufrechterhaltung der Chemotaxis;
leichtere
Oxidation von Mikroorganismen;
antioxidativer Schutz der Membranen
der Granulozyten vor freien Radikalen;
Vitamin K: für die Verbindung
zwischen anorganischen Mineral salzen und organischer Matrix sind
Calcium bindende Proteine verantwortlich. Die Bildung dieser Proteine
ist vom Vitamin D und Vitamin K abhängig. Vitamin K ist somit für den Calciumeinbau
in den Knochen erforderlich. Vitamin K ist z. B. in Aloe vera enthalten.
Calcium:
Hauptbestandteil der anorganischen Knochenmasse als Apatit-Kristall,
verantwortlich für
die Festigkeit des Knochens; Calcium-Resorption wird vermindert
durch phosphatreiche Nahrungsmittel (besonders Wurst- und Fleischwaren);
Calciumausscheidung wird verstärkt
durch den Genuss von Kaffee, Alkohol, Zigaretten, kochsalzreiche
Kost
Kollagenbildung: Vitamin C, Zink, Kupfer und Vitamin B6
sind an der Synthese von Knochenkollagen beteiligt.The effects of some of these components are briefly explained below:
Vitamin D: promotes calcium absorption in the intestine; is involved in bone metabolism; Deficits with reduced exposure to sunlight;
Vitamin D supply 1. via food; mostly too low
2. Own production in the skin with UV light.
Vitamin B6: Bone contains organic matrix, the components of which are bone fibrils. They are responsible for the elasticity of the bones.
B6 is important for the synthesis of bone collagen. There is a positive influence on the bone-building female sex hormone progesterone.
Deficiency: due to environmental toxins such as hydrazines; Various herbicides act as B6 antagonists.
Vitamin C: participation in the synthesis of bone collagen; collagen biosynthesis enhances bone stability;
Activation of vitamin D.
With vitamin C deficiency: reduced bone formation; increased bone resorption; bleeding gingiva, explained by deficient collagen synthesis;
The vitamin C concentration in special white blood cells, the so-called polymorphonuclear neutrophil granulocytes (PMN), is 10-80 times higher than in blood plasma.
The function is:
Maintenance of chemotaxis;
easier oxidation of microorganisms;
antioxidant protection of the membranes of the granulocytes against free radicals;
Vitamin K: Calcium-binding proteins are responsible for the connection between inorganic mineral salts and the organic matrix. The formation of these proteins depends on vitamin D and vitamin K. Vitamin K is therefore necessary for the calcium incorporation in the bones. Vitamin K is e.g. B. contained in aloe vera.
Calcium: main component of the inorganic bone mass as apatite crystal, responsible for the strength of the bone; Calcium absorption is reduced by foods rich in phosphates (especially sausages and meat products); Calcium excretion is intensified through the enjoyment of coffee, alcohol, cigarettes and high-salt foods
Collagen formation: Vitamin C, zinc, copper and vitamin B6 are involved in the synthesis of bone collagen.
Proteine:proteins:
Ausreichende Eiweißzufuhr ist für den Knochenaufbau essentiel:Adequate protein intake is for essential to build up bones:
- 1. Aminosäuren im Eiweiß dienen als Ausgangsmaterial für die organische Knochenmatrix1. amino acids serve in protein as starting material for the organic bone matrix
- 2. Aminosäuren besitzen spezielle Funktionen im Knochenstoffwechsel, zum Beispiel Lysin für die Calciumresorption im Darm und Arginin zum Osteoporoseschutz über die Bildung des Insulin like Growth Faktors I.2. Amino acids have special functions in bone metabolism, for example Lysine for calcium absorption in the intestine and arginine to protect against osteoporosis Formation of the insulin-like growth factor I.
Als erste Knochen zeigen Alveolarfortsatz, Oberschenkelhals und Wirbelkörper Calciumdefizite, d.h. Osteoporose, an. Durch Vitamin D und Calcium ist die Rückbildung des Alveolarknochens möglich. Zahnärzte sind oft als Erste in der Lage, Osteoporose zu erkennen und somit Prävention und Therapie rechtzeitig einzuleiten. Mit den erfindungsgemäßen Zusammensetzungen wird ih nen daher ein geeignetes Mittel in die Hand gegeben.The first bones show alveolar process, Femoral neck and vertebral body Calcium deficits, i.e. Osteoporosis. With vitamin D and calcium is regression of the alveolar bone possible. Are dentists often the first to be able to recognize osteoporosis and thus prevention and initiate therapy in time. With the compositions according to the invention they are given a suitable remedy.
Claims (10)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20220964U DE20220964U1 (en) | 2002-12-09 | 2002-12-09 | Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis |
| DE10257478A DE10257478A1 (en) | 2002-12-09 | 2002-12-09 | Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10257478A DE10257478A1 (en) | 2002-12-09 | 2002-12-09 | Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10257478A1 true DE10257478A1 (en) | 2004-07-08 |
Family
ID=32477483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10257478A Withdrawn DE10257478A1 (en) | 2002-12-09 | 2002-12-09 | Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE10257478A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1020183A3 (en) * | 2010-08-05 | 2013-06-04 | Eric Jan Ostwald | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND PREVENTION OF GINGIVITIS AND PARODONTITIS. |
| WO2014161872A1 (en) * | 2013-04-05 | 2014-10-09 | Nestec S.A. | Compositions for use in stimulating bone growth |
| EP2881105A1 (en) * | 2013-12-05 | 2015-06-10 | PM-International AG | Dental care product kit |
| DE102015102094A1 (en) | 2015-01-28 | 2016-07-28 | Madline Gund | Immunosuppressive agent for use in a method for the treatment of gingivitis or periodontitis and pharmaceutical composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000038A1 (en) * | 1999-06-29 | 2001-01-04 | Xel Herbaceuticals | An effervescent green tea extract formulation |
| EP1072265A1 (en) * | 1999-07-20 | 2001-01-31 | MEDIS S.r.l. Medical Infusion Systems | Use of plant polyphenols for treating iron overload |
| DE10109798A1 (en) * | 2001-03-01 | 2002-09-12 | Aventis Pharma Gmbh | Food additives for treatment or prevention of symptoms of diabetes, osteoarthritis, osteoporosis, asthma, mental decline and age related eye disease |
-
2002
- 2002-12-09 DE DE10257478A patent/DE10257478A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000038A1 (en) * | 1999-06-29 | 2001-01-04 | Xel Herbaceuticals | An effervescent green tea extract formulation |
| EP1072265A1 (en) * | 1999-07-20 | 2001-01-31 | MEDIS S.r.l. Medical Infusion Systems | Use of plant polyphenols for treating iron overload |
| DE10109798A1 (en) * | 2001-03-01 | 2002-09-12 | Aventis Pharma Gmbh | Food additives for treatment or prevention of symptoms of diabetes, osteoarthritis, osteoporosis, asthma, mental decline and age related eye disease |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1020183A3 (en) * | 2010-08-05 | 2013-06-04 | Eric Jan Ostwald | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND PREVENTION OF GINGIVITIS AND PARODONTITIS. |
| WO2014161872A1 (en) * | 2013-04-05 | 2014-10-09 | Nestec S.A. | Compositions for use in stimulating bone growth |
| JP2016520544A (en) * | 2013-04-05 | 2016-07-14 | ネステク ソシエテ アノニム | Composition for use in stimulating bone growth |
| AU2014247122B2 (en) * | 2013-04-05 | 2018-12-06 | Société des Produits Nestlé S.A. | Compositions for use in stimulating bone growth |
| JP2020058351A (en) * | 2013-04-05 | 2020-04-16 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Compositions for use in stimulating bone growth |
| US10675290B2 (en) | 2013-04-05 | 2020-06-09 | Societe Des Produits Nestle S.A. | Compositions for use in stimulating bone growth |
| US11166965B2 (en) | 2013-04-05 | 2021-11-09 | Societe Des Produits Nestle S.A. | Compositions for use in stimulating bone growth |
| JP2022031660A (en) * | 2013-04-05 | 2022-02-22 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Composition for use in stimulating bone growth |
| JP2024150494A (en) * | 2013-04-05 | 2024-10-23 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Compositions for use in stimulating bone growth - Patents.com |
| EP2881105A1 (en) * | 2013-12-05 | 2015-06-10 | PM-International AG | Dental care product kit |
| DE102015102094A1 (en) | 2015-01-28 | 2016-07-28 | Madline Gund | Immunosuppressive agent for use in a method for the treatment of gingivitis or periodontitis and pharmaceutical composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6503483B2 (en) | Dental formulation | |
| DE102008036954B4 (en) | Use of an amino sugar-containing composition | |
| EP0874618A1 (en) | Preparation for improving hair growth, the skin structure and/or nail regeneration | |
| KR20180089003A (en) | Toothpaste composition comprising natural extracts and preparing method thereof | |
| KR20210122554A (en) | Nutritional composition for pets for prevention and improvement of periodontal disease and nutritional agent manufactured thereby | |
| US20040214750A1 (en) | Medicaments for healing skin conditions in humans | |
| CN106691883A (en) | Toothpaste and preparation method thereof | |
| KR101517095B1 (en) | Periodontal diseases treatment and prevention composition using the natural extracts | |
| WO2002076433A1 (en) | Dental formulation | |
| KR102377359B1 (en) | Soap compositions containing natural ingredients | |
| DE102015218892A1 (en) | Application mixture for increasing the effect of antiseptics and / or disinfectants, application agent with the content of the application mixture and the use of this mixture | |
| DE10257478A1 (en) | Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis | |
| CN108434174B (en) | A kind of oral spray for assisting dental caries treatment and prevention of dental caries and preparation method thereof | |
| DE4028957C2 (en) | Therapeutic for the mouth area | |
| EP0757554B1 (en) | Lollipop with tooth plaque neutralising effect | |
| DE20220964U1 (en) | Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis | |
| KR20230040932A (en) | Composition for removing or improving oral malodor | |
| WO2010082600A1 (en) | Agent for maintaining healthy state of periodontal tissue comprising oleuropein and degraded product thereof | |
| Abuljadayel | The Potential Uses of Baobab Tree's Medicinal Effects in Dentistry: A Literature Review | |
| Ramya et al. | Anti inflammatory and antioxidant activity of Stevia and peppermint herbal formulation | |
| KR101910716B1 (en) | Mouthwash containing green tea | |
| DE102020104279A1 (en) | Collagen hydrolyzate as an active ingredient against periodontitis or gingivitis | |
| US20210290711A1 (en) | Hempseed oil compositions | |
| EP2900209B1 (en) | Composition containing lysine as a nutritional supplement or treatment in the case of herpes | |
| DE3821922A1 (en) | Pharmaceutical foodstuff for curative purposes and process for its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8130 | Withdrawal | ||
| 8165 | Unexamined publication of following application revoked |